Printer Friendly

IMMUNOGEN, INC. NAMES DIXIE ESSELTINE, M.D., DIRECTOR OF ONCOLOGY

 IMMUNOGEN, INC. NAMES DIXIE ESSELTINE, M.D., DIRECTOR OF ONCOLOGY
 CAMBRIDGE, Mass., Sept. 28 /PRNewswire/ -- ImmunoGen, Inc. (NASDAQ: IMGN) today announced the appointment of Dixie Esseltine, M.D., F.R.C.P.(C), to the newly created position of director of oncology. Dr. Esseltine joins ImmunoGen from Ortho-McNeil, a subsidiary of Johnson & Johnson, where she was associate director, clinical research and development.
 "Dr. Esseltine is a distinguished member of the hematology-oncology community," notes President and Chief Operating Officer Don McCarren. "Her extensive clinical and academic experience in the study and treatment of cancer and hematologic disease will be a great asset to ImmunoGen." McCarren adds that, "It is important to continue the expansion of our Medical Affairs Department at this stage in our development." ImmunoGen currently has three products in clinical trials and has filed an Investigational New Drug Application with the Food and Drug Administration to begin human testing of a fourth product. The company's lead product, Ond product, Oncolysin S, is expected to enter dose-ranging Phase II studies in the treatment of small-cell lung cancer by year-end.
 From 1980 to 1990, Dr. Esseltine was assistant director of hematology, Montreal Children's Hospital, and associate professor of pediatrics at McGill University, Montreal. She was a Fellow in Medical Oncology at Albany Medical College, New York, and completed residency training in internal medicine and hematology at teaching hospitals of McGill University. Her internship was at the Queen Elizabeth Hospital, Montreal. Dr. Esseltine received her M.D. in 1972 from the University of Western Ontario, where she was class valedictorian.
 ImmunoGen, Inc. develops innovative therapeutics for the treatment of cancer and immune-mediated diseases. The company produces proprietary toxins conjugated to highly specific targeting agents which search out and destroy cancer cells. The company's first generation of products, the Oncolysins, are each comprised of a highly specific monoclonal antibody linked to blocked ricin, a proprietary derivative of the powerful plant toxin ricin.
 -0- 9/28/92
 /CONTACT: Mark Ratner, director, external communications of ImmunoGen, 617-661-9312/
 (IMGN) CO: ImmunoGen, Inc. ST: Massachusetts IN: MTC SU: PER


CH -- NE001 -- 3822 09/28/92 08:29 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 28, 1992
Words:351
Previous Article:GENETICS INSTITUTE TO SELL ITS RHODE ISLAND MANUFACTURING INTEREST
Next Article:WARRANTECH SIGNS DESEAR'S
Topics:


Related Articles
IMMUNOGEN EXPANDS MANAGEMENT TEAM: DONALD J. MCCARREN NAMED PRESIDENT AND CHIEF OPERATING OFFICER
IMMUNOGEN, INC. NAMES ROBERT E. TELLIS VICE PRESIDENT OF CORPORATE DEVELOPMENT
IMMUNOGEN, INC. NAMES JOHN A. KNOX DIRECTOR OF HUMAN RESOURCES
VIROTECH, INC. NAMES MEDICAL ADVISORY BOARD
AGOURON PHARMACEUTICALS NAMES ONCOLOGY ADVISORY BOARD
IMMUNOGEN, INC., PROMOTES TWO IN RESEARCH AND DEVELOPMENT AND ANNOUNCES THE RESIGNATION OF ITS VICE PRESIDENT, CORPORATE DEVELOPMENT
IMMUNOGEN PROMOTES DIXIE ESSELTINE, M.D., TO VICE PRESIDENT, MEDICAL AFFAIRS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters